#MAGNESIUM TOXICITY ANTIDOTE TRIAL#Recently, the 2-year outcome following the use of MgSO 4 in the Magpie trial was published. The effect of MgSO 4 on perinatal outcomes was also studied, demonstrating significantly improved outcomes for newborns compared to phenytoin. Use of MgSO 4 in patients with severe pre-eclampsia reduced the risk of progression to eclampsia by more than half and reduced maternal mortality. Women treated with MgSO 4 had a 52% and 67% lower recurrence of convulsions than those treated with diazepam and phenytoin, respectively. Four centers in Nigeria-Ibadan, Sagamu, Port Harcourt and Sokoto-participated in the study. The trial (also called Magpie trial) was a randomized, placebo-controlled study that enrolled over 10,000 women in 33 countries and across a wide variety of clinical settings. Magnesium sulphate (MgSO 4 ) was first introduced to control convulsions in 1925, but it was the Collaborative Eclampsia Trial in 1995 that confirmed the efficacy of MgSO 4 in the treatment of severe preeclampsia and eclampsia. Yet, prenatal care and supervision of delivery by trained birth attendants are said to be the best and cost-effective means of reducing maternal and perinatal mortality and morbidity. When delivery care is sought, it is done late, after a lot of delays and this contributes to maternal mortality. In addition, the World Health Organization (WHO) estimates that only 40% of births in developing countries take place in health facilities. The opportunity to detect women at the pre-eclamptic phase is therefore usually lost. In the developing countries, there is low utilization of both antenatal and intrapartum care and the patients may present to the hospital only as a last resort. What is quite clear is that eclampsia is a major killer of pregnant women in our environment and all efforts aimed at reducing its menace are welcome. #MAGNESIUM TOXICITY ANTIDOTE REGISTRATION#However in an environment where registration of birth and death are not compulsory, these figures are often all that is available to give an indication of the real picture. It could indeed be argued that these are merely hospital statistics which do not reflect what is really happening in the community. In Birnin Kudu, eclampsia contributed 43.1% of all maternal deaths, while in Yenagoa and Ilorin, the contribution was 40% and 27.5%, respectively. The review of maternal deaths in Kano state for example showed that eclampsia was the most common cause of the deaths and contributed 46.3% of all the deaths in one study and 31.3% in another. Eclampsia has been noted to be among the most common causes of maternal mortality in Nigeria. Nigeria has one of the highest rates of maternal mortality in the world. It is estimated that every year eclampsia is associated with about 50,000 maternal deaths worldwide, most of which occur in developing countries. Available from: Įclampsia is a common cause of maternal mortality worldwide but particularly in the developing countries. The use of magnesium sulphate for the treatment of severe pre-eclampsia and eclampsia. Keywords: Eclampsia maternal mortality magnesium sulphate training Il y a besoin de davantage de formation des travailleurs de santé sur l'utilisation de cette drogue importante. Résultats: le médicament est administré par le schéma thérapeutique Pritchard ou Zuspan bien que les modifications apportées à les deux protocoles ont été signalés.Ĭonclusion: Un protocole national nigérian a été développé sur son utilisation. Method: en Cet article une revue documentaire a été effectuée sur la contribution de traiter les prééclampsies et éclampsie à la mortalité maternelle et comment il peut être ralenti par l'utilisation de sulfate de magnésium. #MAGNESIUM TOXICITY ANTIDOTE PLUS#Il y a maintenant preuve que le sulfate de magnésium est le plus efficace Antiépileptique. Il est nécessaire de fournir le plus une gestion efficace de patients pre-eclamptic et eclamptic. Abstract in FrenchĬontexte: Pre-eclampsia et éclampsie sont importantes causes de morbidité maternelle et périnatale et mortalité dans les pays en développement. #MAGNESIUM TOXICITY ANTIDOTE HOW TO#There is need for further training of health workers on how to use this important drug. Results : The drug is administered by the Pritchard or Zuspan regimen, although modifications in the two protocols have been reported.Ĭonclusion : A Nigerian national protocol has been developed on its use. Method : In this article, a literature review was made on the contribution of pre-eclampsia and eclampsia to maternal mortality and how it can be curtailed by the use of magnesium sulphate. There is now evidence that magnesium sulphate is the most effective anticonvulsant. There is need to provide the most effective management to pre-eclamptic and eclamptic patients. Background : Pre-eclampsia and eclampsia are important causes of maternal and perinatal morbidity and mortality in the developing countries.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |